Non-Cochrane · intervention · PM41584371
Interventions to Chemotherapy and Radiotherapy Induced Oral Mucositis: a Systematic Review and Meta-analysis.
Pereira Cristiana Palmela, Marques Inês, Martins João Paulo · Acta stomatologica Croatica · 2025 · PubMed · doi:10.15644/asc59/4/6
Findings
Population Adults with cancer receiving chemotherapy and/or radiotherapy
49 findings
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Age: 44-55 years | OR 0.33 [0.1, 1.1] GRADE not reported 6 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Oral mucositis scale: RTOG | OR 0.38 [0.07, 2.13] GRADE not reported 5 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Region: South America | OR 0.68 [0.21, 2.22] GRADE not reported 3 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Treatment regimen: radiotherapy (RT) | OR 0.28 [0.15, 0.53] GRADE not reported 3 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Sex: %Female >35% | MD -0.57 [-0.86, -0.28] GRADE not reported 6 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Cancer type: Other | MD -0.17 [-0.37, 0.03] GRADE not reported 3 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Age: 44-55 years | MD -0.48 [-0.8, -0.16] GRADE not reported 6 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Oral mucositis scale: NCI-CTCAE | MD -0.76 [-0.98, -0.54] GRADE not reported 4 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Oral mucositis scale: WHO | OR 0.33 [0.2, 0.53] GRADE not reported 10 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Oral mucositis scale: WHO | MD -0.43 [-0.78, -0.09] GRADE not reported 10 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Sex: %Female >=25% | OR 0.22 [0.12, 0.42] GRADE not reported 10 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Oral mucositis scale: NCI-CTCAE | OR 0.27 [0.17, 0.42] GRADE not reported 4 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Sex: %Female <=35% | MD -0.49 [-0.9, -0.08] GRADE not reported 8 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Age: 56-67 years | MD -0.5 [-0.77, -0.23] GRADE not reported 7 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Treatment regimen: chemoradiotherapy (CRT) | MD -0.42 [-0.71, -0.12] GRADE not reported 10 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Cancer type: Head and neck | MD -0.52 [-0.81, -0.23] GRADE not reported 12 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Region: South Asia | MD -0.49 [-1.06, 0.07] GRADE not reported 5 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Sensitivity analysis excluding high risk of bias studies | OR 0.33 [0.17, 0.65] GRADE not reported 15 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Region: East and South Asia | OR 0.08 [0.03, 0.27] GRADE not reported 4 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Treatment regimen: radiotherapy (RT) | MD -0.84 [-1.32, -0.35] GRADE not reported 3 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Region: Middle East and North Africa | MD -0.37 [-0.62, -0.13] GRADE not reported 4 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Region: South Asia | OR 0.39 [0.19, 0.83] GRADE not reported 4 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries | OR 0.31 [0.19, 0.49] GRADE not reported 20 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Treatment regimen: chemotherapy (CT) | OR 0.27 [0.16, 0.47] GRADE not reported 5 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Treatment regimen: chemotherapy (CT) | MD -0.26 [-0.62, 0.11] GRADE not reported 3 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Treatment regimen: chemoradiotherapy (CRT) | OR 0.34 [0.17, 0.68] GRADE not reported 12 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries | MD -0.47 [-0.71, -0.24] GRADE not reported 16 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Region: East and South Asia | MD -0.65 [-1.11, -0.18] GRADE not reported 3 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Region: USA | OR 0.31 [0.19, 0.51] GRADE not reported 3 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Region: South America | MD -0.41 [-0.88, 0.06] GRADE not reported 4 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Age: 56-67 years | OR 0.36 [0.23, 0.58] GRADE not reported 9 studies |
| Any pharmacological or non-pharmacological intervention for oral mucositis | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Sex: %Female <25% | OR 0.41 [0.23, 0.74] GRADE not reported 10 studies |
| Anti-inflammatory, antimicrobial and coating agents | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention groups | MD -0.26 [-0.82, 0.31] GRADE not reported 3 studies |
| Anti-inflammatory, antimicrobial and coating agents | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention groups | OR 0.44 [0.24, 0.8] GRADE not reported 6 studies |
| Natural agents (honey, curcumin, green tea, probiotics and others) | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention groups | MD -0.51 [-0.81, -0.2] GRADE not reported 10 studies |
| Natural agents (honey, curcumin, green tea, probiotics and others) | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention groups | OR 0.26 [0.12, 0.54] GRADE not reported 11 studies |
| Non-pharmacological interventions (cryotherapy, photobiomodulation, early nutrition) | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention type | MD -0.56 [-0.98, -0.14] GRADE not reported 3 studies |
| Non-pharmacological interventions (cryotherapy, photobiomodulation, early nutrition) | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention groups | OR 0.21 [0.1, 0.45] GRADE not reported 3 studies |
| Non-pharmacological interventions (cryotherapy, photobiomodulation, early nutrition) | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention groups | MD -0.56 [-0.98, -0.14] GRADE not reported 3 studies |
| Non-pharmacological interventions (cryotherapy, photobiomodulation, early nutrition) | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention type | OR 0.26 [0.13, 0.5] GRADE not reported 4 studies |
| Pharmacological interventions | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention type | OR 0.32 [0.18, 0.55] GRADE not reported 16 studies |
| Pharmacological interventions | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Intervention type | MD -0.45 [-0.72, -0.18] GRADE not reported 13 studies |
| Capsule or pill delivered interventions | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Delivery method | MD -0.73 [-1.04, -0.42] GRADE not reported 3 studies |
| Capsule or pill delivered interventions | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Delivery method | OR 0.27 [0.17, 0.43] GRADE not reported 4 studies |
| Topical non-pharmacological interventions | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Delivery method | MD -0.56 [-0.98, -0.14] GRADE not reported 3 studies |
| Topical non-pharmacological interventions | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Delivery method | OR 0.26 [0.13, 0.5] GRADE not reported 4 studies |
| Topical pharmacological interventions (mouthwashes, gels) | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Delivery method | OR 0.42 [0.18, 1.01] GRADE not reported 7 studies |
| Topical pharmacological interventions (mouthwashes, gels) | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis severity (mucositis scale score) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Delivery method | MD -0.36 [-0.72, 0.0] GRADE not reported 8 studies |
| Intravenously delivered interventions | Control (placebo, routine oral care, no treatment, or active comparator) | Oral mucositis (dichotomous: incidence/severity grade) Post-baseline follow-up (one or several timepoints) · Oncology patients, mainly head and neck cancer, 11 countries · Delivery method | OR 0.17 [0.06, 0.5] GRADE not reported 4 studies |
Included primary studies 45
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Azrudheen 2023 Effectiveness of Application / of Flavored (Honey and Tulsi) Ice Chips on Reduction of Oral Mucositis Among Chemo Therapy Receiving Patients DOI:10.18137/cardiometry.2023.26.690695 | 2023 | this review only | not stated | not extracted yet |
| Banega 2023 Modulation of radiant oncological therapy through the intervention with substances of vegetable origin DOI:10.15392/2319-0612.2023.2261 | 2023 | this review only | not stated | not extracted yet |
| Bonomi 2023 PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving… DOI:10.1016/j.ijrobp.2022.12.031 | 2023 | this review only | not stated | not extracted yet |
| Bonomi 2023 PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving… PMID:36646388 | 2023 | this review only | not stated | not extracted yet |
| Chin 2023 Efficacy of polyacrylate silver salt/polyvinylpyrrolidone-based liquid oral gel in management of concurrence chemoradiotherapy-induced… DOI:10.1016/j.jfma.2022.12.007 | 2023 | this review only | not stated | not extracted yet |
| Chin 2023 Efficacy of polyacrylate silver salt/polyvinylpyrrolidone-based liquid oral gel in management of concurrence chemoradiotherapy-induced… PMID:36623972 | 2023 | this review only | not stated | not extracted yet |
| ChunLing 2019 A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy… PMID:30521105 | 2019 | this review only | not stated | not extracted yet |
| de Cassia 2022 Comparative randomized trial study about the efficacy of photobiomodulation and curcumin antimicrobial photodynamic therapy as a… PMID:35608694 | 2022 | this review only | not stated | not extracted yet |
| de Cassia Dias Viana Andrade 2022 Comparative randomized trial study about the efficacy of photobiomodulation and curcumin antimicrobial photodynamic therapy as a… DOI:10.1007/s00520-022-07127-x | 2022 | this review only | not stated | not extracted yet |
| Delavarian 2019 Oral administration of nanomicelle curcumin in the prevention of radiotherapy‐induced mucositis in head and neck cancers DOI:10.1111/scd.12358 | 2019 | this review only | not stated | not extracted yet |
| Delavarian 2019 Oral administration of nanomicelle curcumin in the prevention of radiotherapy-induced mucositis in head and neck cancers. PMID:30761565 | 2019 | this review only | not stated | not extracted yet |
| Fernandes 2022 Brazilian organic propolis for prevention and treatment of radiation-related oral acute toxicities in head and neck cancer patients: A… DOI:10.3389/fphar.2022.973255 | 2022 | this review only | not stated | not extracted yet |
| Fernandes 2022 Brazilian organic propolis for prevention and treatment of radiation-related oral acute toxicities in head and neck cancer patients: A… PMID:36278178 | 2022 | this review only | not stated | not extracted yet |
| Habsari 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hasheminasab 2020 Effects of a Plantago ovata-based herbal compound in prevention and treatment of oral mucositis in patients with breast cancer receiving… DOI:10.1016/j.joim.2020.02.008 | 2020 | this review only | not stated | not extracted yet |
| Hasheminasab 2020 Effects of a Plantago ovata-based herbal compound in prevention and treatment of oral mucositis in patients with breast cancer receiving… PMID:32268991 | 2020 | this review only | not stated | not extracted yet |
| Jiang (ChunLing) 2019 A randomized, double‐blind, placebo‐controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy… DOI:10.1002/cncr.31907 | 2018 | this review only | not stated | not extracted yet |
| Kaur 2024 A QUASI-EXPERIMENTAL STUDY TO ASSESS THE EFFECTIVENESS OF TOPICAL APPLICATION OF HONEY ON ORAL MUCOSITIS AMONG HEAD AND NECK CANCER… DOI:10.47211/idcij.2024.v11i01.002 | 2024 | this review only | not stated | not extracted yet |
| Kia 2021 Effects of nanomicelle curcumin capsules on prevention and treatment of oral mucosits in patients under chemotherapy with or without head… DOI:10.1186/s12906-021-03400-4 | 2021 | this review only | not stated | not extracted yet |
| Kia 2021 Effects of nanomicelle curcumin capsules on prevention and treatment of oral mucosits in patients under chemotherapy with or without head… PMID:34521398 | 2021 | this review only | not stated | not extracted yet |
| Kurane 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Lopes 2021 Cost-effectiveness randomized clinical trial on the effect of photobiomodulation therapy for prevention of radiotherapy-induced severe… PMID:32621262 | 2021 | this review only | not stated | not extracted yet |
| Lopes 2023 Effects of a mucoadhesive phytomedicine (Curcuma longa L. and Bidens pilosa L.) on radiotherapy-induced oral mucositis and quality of life… PMID:37566179 | 2023 | this review only | not stated | not extracted yet |
| Lopes Martins 2021 Cost-effectiveness randomized clinical trial on the effect of photobiomodulation therapy for prevention of radiotherapy-induced severe… DOI:10.1007/s00520-020-05607-6 | 2020 | this review only | not stated | not extracted yet |
| Martins 2023 Effects of a mucoadhesive phytomedicine (Curcuma longa L. and Bidens pilosa L.) on radiotherapy-induced oral mucositis and quality of life… DOI:10.1007/s00520-023-07971-5 | 2023 | this review only | not stated | not extracted yet |
| Mirza 2022 Efficacy of Bacillus clausii UBBC - 07 spores in the amelioration of oral mucositis in head and neck cancer patients undergoing radiation… DOI:10.1016/j.ctarc.2022.100523 | 2022 | this review only | not stated | not extracted yet |
| Mirza 2022 Efficacy of Bacillus clausii UBBC - 07 spores in the amelioration of oral mucositis in head and neck cancer patients undergoing radiation… PMID:35101832 | 2022 | this review only | not stated | not extracted yet |
| Pakravan 2019 A novel formulation for radiotherapy-induced oral mucositis: Triamcinolone acetonide mucoadhesive film. PMID:31523249 | 2019 | this review only | not stated | not extracted yet |
| Ravindra 2019 Effectiveness of Chlorhexidine vs KMnO<sub>4</sub> Oral care on Oral mucositis among Head and neck cancer patients admitted in Oncology… DOI:10.5958/2454-2660.2019.00011.5 | 2019 | this review only | not stated | not extracted yet |
| Saniya 2023 Evaluating Ayurvedic mouthwash and soda-salt mouthwash for oral mucositis in head and neck cancer: A randomized controlled trial DOI:10.1016/j.jaim.2023.100829 | 2023 | this review only | not stated | not extracted yet |
| Saniya 2023 Evaluating Ayurvedic mouthwash and soda-salt mouthwash for oral mucositis in head and neck cancer: A randomized controlled trial. PMID:38029523 | 2023 | this review only | not stated | not extracted yet |
| Selvi 2019 A Study to assess the effectiveness of normal saline mouthwash on the prevention of Oral Mucositis among patients receiving chemotherapy… DOI:10.5958/2454-2660.2019.00009.7 | 2019 | this review only | not stated | not extracted yet |
| Serageldin 2023 The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study DOI:10.1007/s40264-023-01305-4 | 2023 | this review only | not stated | not extracted yet |
| Serageldin 2023 The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study. PMID:37131014 | 2023 | this review only | not stated | not extracted yet |
| Shaolong 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Shin 2019 The Effects of Oral Cryotherapy on Oral Mucositis, Reactive Oxygen Series, Inflammatory Cytokines, and Oral Comfort in Gynecologic Cancer… DOI:10.4040/jkan.2019.49.2.149 | 2019 | this review only | not stated | not extracted yet |
| Shin 2019 [The Effects of Oral Cryotherapy on Oral Mucositis, Reactive Oxygen Series, Inflammatory Cytokines, and Oral Comfort in Gynecologic Cancer… PMID:31064968 | 2019 | this review only | not stated | not extracted yet |
| Srinivasan 2019 (benzydamine) matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Srinivasan 2019 (clotrimazole) matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Srinivasan 2019a matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Srinivasan 2019b matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Thomas 2023 Randomized Control Study of the Effects of Turmeric Mouthwash on Oral Health Status, Treatment-Induced Mucositis, and Associated Oral… DOI:10.1097/ncc.0000000000001149 | 2022 | this review only | not stated | not extracted yet |
| Thomas 2023 Randomized Control Study of the Effects of Turmeric Mouthwash on Oral Health Status, Treatment-Induced Mucositis, and Associated Oral… PMID:36066336 | 2023 | this review only | not stated | not extracted yet |
| Wei 2024 Effects of early nutritional intervention on oral mucositis and basic conditions in patients receiving radiotherapy for head and neck… DOI:10.1016/j.clnu.2024.05.029 | 2024 | this review only | not stated | not extracted yet |
| Wei 2024 Effects of early nutritional intervention on oral mucositis and basic conditions in patients receiving radiotherapy for head and neck… PMID:38833872 | 2024 | this review only | not stated | not extracted yet |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Adults (18 years or older) with cancer undergoing chemotherapy and/or radiotherapy, with oral mucositis of varying severity (WHO, NCI-CTCAE, RTOG) | Adults with cancer receiving chemotherapy and/or radiotherapy (1,499 participants; 30 studies from 27 publications; 11 countries; mostly head and neck cancer) |
| Intervention | Any pharmacological or non-pharmacological intervention for prevention or treatment of oral mucositis (MASCC/ISOO categories: basic oral care, growth factors and cytokines, anti-inflammatory agents, antimicrobials, analgesics and anesthetics, mucosal coating agents, natural agents, cryotherapy, photobiomodulation/laser, amifostine) | Natural agents (honey, green tea, probiotics, curcumin, vitamin E, herbal compounds, ayurvedic and saline mouthwash, compound Kushen); anti-inflammatory, antimicrobial and coating agents (RRx-001 with dexamethasone, polyacrylate silver salt, triamcinolone, chlorhexidine, metformin, clotrimazole, benzydamine); non-pharmacological (cryotherapy, photobiomodulation, early nutritional intervention) |
| Comparison | Placebo, standard/routine care, no treatment, or head-to-head comparison between interventions | Placebo, routine oral care, no intervention, active comparators (e.g., nystatin, benzydamine, KMnO4, saline, soda bicarbonate mouthwash) |
| Outcomes | Primary: oral mucositis incidence and severity (any, moderate-to-severe, severe). Secondary: pain intensity, time to onset, remission of mucositis | Oral mucositis severity (mucositis scale, mean difference; 16 studies) and oral mucositis dichotomous (odds ratio; 20 studies) |
| Study designs | Randomized controlled trials | Randomized controlled trials (27 publications, 30 studies/arms) |
| Timing | Not specified | Post-baseline follow-up: 1 to 16 time points per study |
AMSTAR 2 items
Two independent extractors rated each item. Their ratings are shown side by side because they have not been reconciled yet. The overall rating follows Shea et al. 2017: one critical flaw gives Low, more than one gives Critically Low.
| Item | Extractor A | Extractor B | Agree |
|---|---|---|---|
| 1Research question includes PICO components | Yes | Yes | yes |
| 2Protocol established before the reviewcritical | Partial Yes | Partial Yes | yes |
| 3Choice of study designs explained | No | No | yes |
| 4Comprehensive literature searchcritical | No | No | yes |
| 5Study selection in duplicate | Yes | Yes | yes |
| 6Data extraction in duplicate | Yes | Yes | yes |
| 7List of excluded studies with reasonscritical | Yes | Yes | yes |
| 8Included studies described in detail | Partial Yes | Partial Yes | yes |
| 9Risk of bias assessed satisfactorilycritical | RCT: Yes · NRSI: N/A | NRSI: N/A · RCT: Yes | no |
| 10Funding of included studies reported | No | No | yes |
| 11Appropriate meta-analysis methodscritical | RCT: No · NRSI: N/A | NRSI: N/A · RCT: No | no |
| 12Impact of risk of bias on the pooled results | Yes | Yes | yes |
| 13Risk of bias accounted for in interpretationcritical | No | No | yes |
| 14Heterogeneity explained | Yes | Yes | yes |
| 15Publication bias investigatedcritical | Yes | Yes | yes |
| 16Conflicts of interest reported | Yes | Yes | yes |
| Overall | Critically Low | Critically Low | yes |